A 28-year-old woman with bipolar I disorder has been on olanzapine 15 mg/day for 10 months. She presents with amenorrhea for 3 months, galactorrhea, and decreased libido. Her serum prolactin is 68 ng/mL (normal <25 ng/mL in women). She denies pregnancy, and thyroid function tests are normal. Which mechanism best explains her hyperprolactinemia and why is this a concern in long-term antipsychotic therapy?

Explanation

## Antipsychotic-Induced Hyperprolactinemia ### Mechanism of Prolactin Elevation **Key Point:** Antipsychotics block dopamine D2 receptors in the **tuberoinfundibular pathway** (hypothalamic-pituitary axis). Dopamine normally acts as prolactin-inhibiting factor (PIF). D2 blockade removes this tonic inhibition, leading to uncontrolled prolactin release from lactotroph cells. ### Antipsychotics Ranked by Hyperprolactinemia Risk | Antipsychotic | Prolactin Risk | Mechanism | |---------------|----------------|----------| | **Risperidone** | Very High | High D2 affinity, poor blood-brain barrier selectivity | | **Paliperidone** | Very High | Active metabolite of risperidone | | **Amisulpride** | Very High | Selective D2/D3 antagonist | | **Olanzapine** | Moderate-High | D2 antagonism + some 5-HT2 effects | | **Quetiapine** | Low | Weak D2 affinity, rapid dissociation | | **Clozapine** | Low | Minimal D2 affinity in tuberoinfundibular region | | **Aripiprazole** | Low-Minimal | D2 partial agonist (maintains dopaminergic tone) | **Clinical Pearl:** This patient's prolactin of 68 ng/mL is significantly elevated. Olanzapine causes moderate-to-high prolactin elevation, though risperidone and paliperidone are the worst offenders. ### Clinical Consequences of Chronic Hyperprolactinemia **High-Yield:** Long-term hyperprolactinemia carries serious health risks: 1. **Hypogonadism** - Amenorrhea/oligomenorrhea in women (as in this case) - Erectile dysfunction and decreased libido in men - Mechanism: Prolactin inhibits GnRH secretion 2. **Bone Health** - **Osteoporosis and increased fracture risk** (due to hypogonadism-induced loss of bone mineral density) - Prolactin itself has weak direct effects on bone, but hypogonadism is the major driver 3. **Malignancy Risk** - **Breast cancer:** Prolactin is a growth factor for breast tissue; chronic elevation increases risk - Prolactinoma development (rare but documented) 4. **Metabolic Effects** - Weight gain (prolactin stimulates appetite) - Insulin resistance (compounded by antipsychotic metabolic effects) 5. **Sexual Dysfunction** - Decreased libido, erectile dysfunction, anorgasmia - Major cause of medication non-adherence ### Management Approach ```mermaid flowchart TD A[Antipsychotic-induced hyperprolactinemia]:::outcome --> B{Prolactin level & symptoms?}:::decision B -->|Mild elevation, asymptomatic| C[Monitor prolactin annually]:::action B -->|Moderate-severe or symptomatic| D{Switch possible?}:::decision D -->|Yes| E[Switch to low-prolactin agent<br/>aripiprazole, quetiapine, clozapine]:::action D -->|No| F[Add dopamine agonist<br/>bromocriptine or cabergoline]:::action E --> G[Recheck prolactin in 3 months]:::action F --> G G --> H{Normalized?}:::decision H -->|Yes| I[Continue monitoring]:::action H -->|No| J[Optimize dose or switch agent]:::action ``` **Tip:** Aripiprazole is the preferred switch agent because it is a **D2 partial agonist** — it maintains dopaminergic tone in the tuberoinfundibular pathway while blocking D2 in mesolimbic/mesocortical regions, thus reducing prolactin without worsening psychotic symptoms. ### Why This Case Warrants Action This patient has: - **Prolactin 68 ng/mL** (markedly elevated; normal <25 ng/mL) - **Amenorrhea for 3 months** (significant hypogonadal effect) - **Galactorrhea and decreased libido** (quality-of-life impact) - **10 months of exposure** (long enough to risk osteoporosis) **Recommendation:** Switch to aripiprazole or add a dopamine agonist (bromocriptine 2.5–5 mg daily or cabergoline 0.25–0.5 mg twice weekly). [cite:Stahl's Essential Psychopharmacology 6e Ch 5; Harrison 21e Ch 470]